Comparative Diagnostic Performance of Color Doppler Flow Imaging, MicroFlow Imaging and Contrast-enhanced Ultrasound in Solid Renal Tumors

RATIONALE AND OBJECTIVES

Accurate distinguish malignant from benign renal masses remains a challenge for radiologists. The purpose of this study was to evaluate the value of Color Doppler Flow Imaging (CDFI), MicroFlow Imaging (MFI) and Contrast-enhanced Ultrasound (CEUS) in diagnosing solid renal tumors.

MATERIALS AND METHODS

A total of 291 patients with 300 solid renal tumors pathologically confirmed were retrospectively analyzed between January 2020 and December 2022. Each patient underwent CDFI, MFI, and CEUS examinations before surgery. The diagnostic efficacy of CDFI, MFI and CEUS in assessing renal tumors was compared based on blood flow grade, vascular morphology and CEUS characteristics.

RESULTS

MFI identified 243 renal lesions (81%) with blood flow grade (2, 3) and vascular morphology (IV, V), significantly outperforming CDFI, which detected 147 cases (49%). MFI demonstrated statistically significant differences in detecting blood flow signals and predicting renal malignancy compared to CDFI (p < 0.001). In CEUS examination, significant differences were observed in wash-in, enhancement intensity, wash-out, and perilesional rim-like enhancement of the contrast agent between malignant and benign renal lesions (all p < 0.001). The areas under the receiver operating characteristic curves (AUCs) for MFI and CEUS were 0.838 and 0.788, respectively, both higher than that for CDFI (0.695). In diagnosing solid renal tumors, MFI and CEUS showed significant differences compared to CDFI (p < 0.05), although no significant difference was found between MFI and CEUS (p = 0.075). The diagnostic accuracy, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of CDFI, MFI and CEUS were as follows: 0.600 vs.0.893 vs.0.920; 0.554 vs. 0.920 vs.0.984; 0.837 vs. 0.755 vs.0.592; 0.946 vs. 0.951 vs.0.925; 0.268 vs. 0.649 vs.0.879.

CONCLUSION

MFI demonstrates higher sensitivity in detecting microvascular signs of renal tumors compared to CDFI. Moreover, MFI exhibits comparable diagnostic performance to CEUS in distinguishing malignant from benign renal masses.

Insights into Radiology Publications

The evolution of modern medicine has been significantly driven by medical and health care research, underscoring the importance of disseminating findings to advance health care. Medical literature, encompassing various publication types such as case reports, review articles, and original research, plays a crucial role in this process by facilitating the communication and discussion of new discoveries. This review article provides a comprehensive guide to understanding and navigating radiologic publications. It examines the various types of radiologic research articles, including case reports and series, pictorial reviews, original research, systematic reviews, and meta-analyses, each of which serve distinct purposes in contributing to the field of radiology. The study adopts the "six honest men" approach-addressing why, who, what, when, where, and how-to elucidate the essential elements of successful radiology research and publication. Key topics include the motivations for publishing, the types of articles suited for different research questions, and strategic considerations for selecting appropriate journals. Additionally, the review highlights the importance of understanding publication timing, journal selection criteria, and the overall publication process, including manuscript preparation and peer review. By offering these insights, the review aims to equip early-career researchers with the knowledge and skills necessary to effectively contribute to radiology literature and advance their academic and professional careers.

Imaging in Renal Cell Carcinoma Detection

INTRODUCTION

Imaging in renal cell carcinoma (RCC) is a constantly evolving landscape. The incidence of RCC has been rising over the years with the improvement in image quality and sensitivity in imaging modalities resulting in "incidentalomas" being detected. We aim to explore the latest advances in imaging for RCC.

METHODS

A literature search was conducted using Medline and Google Scholar, up to May 2024. For each subsection of the manuscript, a separate search was performed using a combination of the following key terms "renal cell carcinoma", "renal mass", "ultrasound", "computed tomography", "magnetic resonance imaging", "18F-Fluorodeoxyglucose PET/CT", "prostate-specific membrane antigen PET/CT", "technetium-99m sestamibi SPECT/CT", "carbonic anhydrase IX", "girentuximab", and "radiomics". Studies that were not in English were excluded. The reference lists of selected manuscripts were checked manually for eligible articles.

RESULTS

The main imaging modalities for RCC currently are ultrasound, computed tomography (CT) and magnetic resonance imaging (MRI). Contrast-enhanced US (CEUS) has emerged as an alternative to CT or MRI for the characterisation of renal masses. Furthermore, there has been significant research in molecular imaging in recent years, including FDG PET, PSMA PET/CT, 99mTc-Sestamibi, and anti-carbonic anhydrase IX monoclonal antibodies/peptides. Radiomics and the use of AI in radiology is a growing area of interest.

CONCLUSIONS

There will be significant change in the field of imaging in RCC as molecular imaging becomes increasingly popular, which reflects a shift in management to a more conservative approach, especially for small renal masses (SRMs). There is the hope that the improvement in imaging will result in less unnecessary invasive surgeries or biopsies being performed for benign or indolent renal lesions.

Cystic Renal Masses: Old and New Paradigms

Cystic renal masses describe a spectrum of lesions with benign and/or malignant features. Cystic renal masses are most often identified incidentally with the Bosniak classification system stratifying their malignant potential. Solid enhancing components most often represent clear cell renal cell carcinoma yet display an indolent natural history relative to pure solid renal masses. This has led to an increased adoption of active surveillance as a management strategy in those who are poor surgical candidates. This article provides a contemporary overview of historical and emerging clinical paradigms in the diagnosis and management of this distinct clinical entity.

Renal Lesion Characterization by Dual-Layer Dual-Energy CT: Comparison of Virtual and True Unenhanced Images

BACKGROUND. Prior studies have provided mixed results for the ability to replace true unenhanced (TUE) images with virtual unenhanced (VUE) images when characterizing renal lesions by dual-energy CT (DECT). Detector-based dual-layer DECT (dlDECT) systems may optimize performance of VUE images for this purpose. OBJECTIVE. The purpose of this article was to compare dual-phase dlDECT examinations evaluated using VUE and TUE images in differentiating cystic and solid renal masses. METHODS. This retrospective study included 110 patients (mean age, 64.3 ± 11.8 years; 46 women, 64 men) who underwent renal-mass protocol dlDECT between July 2018 and February 2022. TUE, VUE, and nephrographic phase image sets were reconstructed. Lesions were diagnosed as solid masses by histopathology or MRI. Lesions were diagnosed as cysts by composite criteria reflecting findings from MRI, ultrasound, and the TUE and nephrographic phase images of the dlDECT examinations. One radiologist measured lesions' attenuation on all dlDECT image sets. Lesion characterization was compared between use of VUE and TUE images, including when considering enhancement of 20 HU or greater to indicate presence of a solid mass. RESULTS. The analysis included 219 lesions (33 solid masses; 186 cysts [132 simple, 20 septate, 34 hyperattenuating]). TUE and VUE attenuation were significantly different for solid masses (33.4 ± 7.1 HU vs 35.4 ± 8.6 HU, p = .002), simple cysts (10.8 ± 5.6 HU vs 7.1 ± 8.1 HU, p < .001), and hyperattenuating cysts (56.3 ± 21.0 HU vs 47.6 ± 16.3 HU, p < .001), but not septate cysts (13.6 ± 8.1 HU vs 14.0 ± 6.8 HU, p = .79). Frequency of enhancement 20 HU or greater when using TUE and VUE images was 90.9% and 90.9% in solid masses, 0.0% and 9.1% in simple cysts, 15.0% and 10.0% in septate cysts, and 11.8% and 38.2% in hyperattenuating cysts. All solid lesions were concordant in terms of enhancement 20 HU or greater when using TUE and VUE images. Twelve simple cysts and nine hyperattenuating cysts showed enhancement of 20 HU or greater when using VUE but not TUE images. CONCLUSION. Use of VUE images reliably detected enhancement in solid masses. However, VUE images underestimated attenuation of simple and hyperattenuating cysts, leading to false-positive findings of enhancement by such lesions. CLINICAL IMPACT. The findings do not support replacement of TUE acquisitions with VUE images when characterizing renal lesions by dlDECT.

Multimodality imaging review of focal renal lesions

Background

Focal lesions of the kidney comprise a spectrum of entities that can be broadly classified as malignant tumors, benign tumors, and non-neoplastic lesions. Malignant tumors include renal cell carcinoma subtypes, urothelial carcinoma, lymphoma, post-transplant lymphoproliferative disease, metastases to the kidney, and rare malignant lesions. Benign tumors include angiomyolipoma (fat-rich and fat-poor) and oncocytoma. Non-neoplastic lesions include infective, inflammatory, and vascular entities. Anatomical variants can also mimic focal masses.

Main body of the abstract

A range of imaging modalities are available to facilitate characterization; ultrasound (US), contrast-enhanced ultrasound (CEUS), computed tomography (CT), magnetic resonance (MR) imaging, and positron emission tomography (PET), each with their own strengths and limitations. Renal lesions are being detected with increasing frequency due to escalating imaging volumes. Accurate diagnosis is central to guiding clinical management and determining prognosis. Certain lesions require intervention, whereas others may be managed conservatively or deemed clinically insignificant. Challenging cases often benefit from a multimodality imaging approach combining the morphology, enhancement and metabolic features.

Short conclusion

Knowledge of the relevant clinical details and key imaging features is crucial for accurate characterization and differentiation of renal lesions.

The role of imaging in the management of renal masses

The wide availability of cross-sectional imaging is responsible for the increased detection of small, usually asymptomatic renal masses. More than 50 % of renal cell carcinomas (RCCs) represent incidental findings on noninvasive imaging. Multimodality imaging, including conventional US, contrast-enhanced US (CEUS), CT and multiparametric MRI (mpMRI) is pivotal in diagnosing and characterizing a renal mass, but also provides information regarding its prognosis, therapeutic management, and follow-up. In this review, imaging data for renal masses that urologists need for accurate treatment planning will be discussed. The role of US, CEUS, CT and mpMRI in the detection and characterization of renal masses, RCC staging and follow-up of surgically treated or untreated localized RCC will be presented. The role of percutaneous image-guided ablation in the management of RCC will be also reviewed.

Bosniak Classification of Cystic Renal Masses, Version 2019: A Pictorial Guide to Clinical Use

Cystic renal masses are commonly encountered in clinical practice. In 2019, the Bosniak classification of cystic renal masses, originally developed for CT, underwent a major revision to incorporate MRI and is referred to as the Bosniak Classification, version 2019. The proposed changes attempt to (a) define renal masses (ie, cystic tumors with less than 25% enhancing tissue) to which the classification should be applied; (b) emphasize specificity for diagnosis of cystic renal cancers, thereby decreasing the number of benign and indolent cystic masses that are unnecessarily treated or imaged further; (c) improve interobserver agreement by defining imaging features, terms, and classes of cystic renal masses; (d) reduce variation in reported malignancy rates for each of the Bosniak classes; (e) incorporate MRI and to some extent US; and (f) be applicable to all cystic renal masses encountered in clinical practice, including those that had been considered indeterminate with the original classification. The authors instruct how, using CT, MRI, and to some extent US, the revised classification can be applied, with representative clinical examples and images. Practical tips, pitfalls to avoid, and decision tree rules are included to help radiologists and other physicians apply the Bosniak Classification, version 2019 and better manage cystic renal masses. An online resource and mobile application are also available for clinical assistance. An invited commentary by Siegel and Cohan is available online. ^©RSNA, 2021.

EFSUMB 2020 Proposal for a Contrast-Enhanced Ultrasound-Adapted Bosniak Cyst Categorization - Position Statement

The well-established Bosniak renal cyst classification is based on contrast-enhanced computed tomography determining the malignant potential of cystic renal lesions. Ultrasound has not been incorporated into this pathway. However, the development of ultrasound contrast agents coupled with the superior resolution of ultrasound makes it possible to redefine the imaging of cystic renal lesions. In this position statement, an EFSUMB Expert Task Force reviews, analyzes, and describes the accumulated knowledge and limitations and presents the current position on the use of ultrasound contrast agents in the evaluation of cystic renal lesions.

Imaging Characterization of Renal Masses

The detection of a renal mass is a relatively frequent occurrence in the daily practice of any Radiology Department. The diagnostic approaches depend on whether the lesion is cystic or solid. Cystic lesions can be managed using the Bosniak classification, while management of solid lesions depends on whether the lesion is well-defined or infiltrative. The approach to well-defined lesions focuses mainly on the differentiation between renal cancer and benign tumors such as angiomyolipoma (AML) and oncocytoma. Differential diagnosis of infiltrative lesions is wider, including primary and secondary malignancies and inflammatory disease, and knowledge of the patient history is essential. Radiologists may establish a possible differential diagnosis based on the imaging features of the renal masses and the clinical history. The aim of this review is to present the contribution of the different imaging techniques and image guided biopsies in the diagnostic management of cystic and solid renal lesions.

ACR Appropriateness Criteria® Indeterminate Renal Mass

Renal masses are increasingly detected in asymptomatic individuals as incidental findings. CT and MRI with intravenous contrast and a dedicated multiphase protocol are the mainstays of evaluation for indeterminate renal masses. A single-phase postcontrast dual-energy CT can be useful when a dedicated multiphase renal protocol CT is not available. Contrast-enhanced ultrasound with microbubble agents is a useful alternative for characterizing renal masses, especially for patients in whom iodinated CT contrast or gadolinium-based MRI contrast is contraindicated. The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed annually by a multidisciplinary expert panel. The guideline development and revision include an extensive analysis of current medical literature from peer reviewed journals and the application of well-established methodologies (RAND/UCLA Appropriateness Method and Grading of Recommendations Assessment, Development, and Evaluation or GRADE) to rate the appropriateness of imaging and treatment procedures for specific clinical scenarios. In those instances where evidence is lacking or equivocal, expert opinion may supplement the available evidence to recommend imaging or treatment.

Clinical Importance of Incidental Homogeneous Renal Masses That Measure 10-40 mm and 21-39 HU at Portal Venous Phase CT: A 12-Institution Retrospective Cohort Study

BACKGROUND. Incidental homogeneous renal masses are frequently encountered at portal venous phase CT. The American College of Radiology Incidental Findings Committee's white paper on renal masses recommends additional imaging for incidental homogeneous renal masses greater than 20 HU, but single-center data and the Bosniak classification version 2019 suggest the optimal attenuation threshold for detecting solid masses should be higher. OBJECTIVE. The purpose of this article is to determine the clinical importance of small (10-40 mm) incidentally detected homogeneous renal masses measuring 21-39 HU at portal venous phase CT. METHODS. We performed a 12-institution retrospective cohort study of adult patients who underwent portal venous phase CT for a nonrenal indication. The date of the first CT at each institution ranged from January 1, 2008, to January 1, 2014. Consecutive reports from 12,167 portal venous phase CT examinations were evaluated. Images were reviewed for 4529 CT examinations whose report described a focal renal mass. Eligible masses were 10-40 mm, well-defined, subjectively homogeneous, and 21-39 HU. Of these, masses that were shown to be solid without macroscopic fat; classified as Bosniak IIF, III, or IV; or confirmed to be malignant were considered clinically important. The reference standard was renal mass protocol CT or MRI, ultrasound of definitively benign cysts or solid masses, single-phase contrast-enhanced CT or unenhanced MRI showing no growth or morphologic change for 5 years or more, or clinical follow-up 5 years or greater. A reference standard was available for 346 masses in 300 patients. The 95% CIs were calculated using the binomial exact method. RESULTS. Eligible masses were identified in 4.2% of patients (514/12,167; 95% CI, 3.9-4.6%). Of 346 masses with a reference standard, none were clinically important (0%; 95% CI, 0-0.9%). Mean mass size was 17 mm; 72% (248/346) measured 21-30 HU, and 28% (98/346) measured 31-39 HU. CONCLUSION. Incidental small homogeneous renal masses measuring 21-39 HU at portal venous phase CT are common and highly likely benign. CLINICAL IMPACT. The change in attenuation threshold signifying the need for additional imaging from greater than 20 HU to greater than 30 HU proposed by the Bosniak classification version 2019 is supported.

Discrimination of papillary renal cell carcinoma from benign proteinaceous cyst based on iodine and water content on rapid kV-switching dual-energy CT

PURPOSE

We aimed to evaluate whether rapid kV-switching dual energy CT (rsDECT) can discriminate between papillary renal cell carcinoma (RCC) and benign proteinaceous cysts (BPCs) based on iodine and water content.

METHODS

Twenty-four patients with histopathologically proven papillary RCC and 38 patients with 41 BPCs were retrospectively included. Patients with BPCs were eligible for inclusion when the cysts were stable in size and appearance for at least 2 years or proved to be a cyst on ultrasound or MRI. All patients underwent delayed phase (70-90 s) rsDECT. Iodine and water content of each lesion was measured on the workstation.

RESULTS

Of papillary RCC patients, 4 (16%) were female and 20 (84%) were male. Mean tumor size was 39±20 mm. Mean iodine and water content was 2.08±0.7 mg/mL and 1021±14 mg/mL, respectively. Of BPC patients, 9 were female and 29 were male. Mean cyst size was 20±7 mm. Mean iodine and water content was 0.82±0.4 mg/mL and 1012±14 mg/mL, respectively. There were significant differences between iodine and water contents of papillary RCCs and BPCs (P < 0.001). The best cutoff of iodine content for differentiating papillary RCC from BPC was 1.21 mg/mL (area under the curve [AUC]=0.97, P < 0.001, sensitivity 96%, specificity 88%, positive predictive value [PPV] 82%, negative predictive value [NPV] 97%, accuracy 91%,); the best cutoff of water content was 1015.5 mg/mL (AUC=0.68, P = 0.016, sensitivity 83%, specificity 56%, PPV 52%, NPV 85%, accuracy 66%).

CONCLUSION

An iodine content threshold of 1.21 mg/mL accurately differentiates papillary RCC from BPCs on a single postcontrast rsDECT. Despite having a high sensitivity, water content has inferior diagnostic accuracy.

Diagnostic Accuracy of Attenuation Difference and Iodine Concentration Thresholds at Rapid-Kilovoltage-Switching Dual-Energy CT for Detection of Enhancement in Renal Masses

OBJECTIVE. The objective of our study was to evaluate iodine concentration and attenuation change in Hounsfield unit (ΔHU) thresholds to diagnose enhancement in renal masses at rapid-kilovoltage-switching dual-energy CT (DECT). MATERIALS AND METHODS. We evaluated 30 consecutive histologically confirmed solid renal masses (including nine papillary renal cell carcinomas [RCCs]) and 27 benign cysts (17 simple and 10 hemorrhagic or proteinaceous cysts) with DECT December 2016 and May 2018. A blinded radiologist measured iodine concentration (in milligrams per milliliter) and ΔHU (attenuation on enhanced CT - attenuation on unenhanced CT) using 70-keV corticomedullary (CM) phase virtual monochromatic and 120-kVp nephrographic (NG) phase images. The accuracies of previously described enhancement thresholds were compared by ROC curve analysis. RESULTS. An iodine concentration of ≥ 2.0 mg/mL and an iodine concentration of ≥ 1.2 mg/mL achieved sensitivity, specificity, and the area under the ROC curve (AUC) of 73.3%, 100.0%, and 0.87 and 86.7%, 100.0%, and 0.93, respectively. On 70-keV CM phase images, ΔHU ≥ 20 HU and ΔHU ≥ 15 HU yielded sensitivity, specificity, and AUC of 80.0%, 100.0%, and 0.90 and 90.0%, 100.0%, and 0.95, respectively. The numbers of incorrectly classified papillary RCCs were as follows: iodine concentration of ≥ 2.0 mg/mL, 77.8% (7/9; range, 0.7-1.6 mg/mL); iodine concentration of ≥ 1.2 mg/mL, 44.4% (4/9; range, 0.7-0.9 mg/mL); ΔHU ≥ 20 HU on 70-keV CM phase images, 66.7% (6/9; range, 4-17 HU); and ΔHU ≥ 15 HU on 70-keV DECT images, 33.3% (3/9; 4-12 HU). No cyst pseudoenhancement occurred on DECT. For 120-kVp NG phase DECT, ΔHU ≥ 20 HU and ΔHU ≥ 15 HU yielded sensitivity, specificity, and AUC of 93.3%, 96.3%, and 0.95 and 100.0%, 88.9%, and 0.94, respectively. With ΔHU ≥ 20 HU, 22.2% (2/9) (range, 15-18 HU) of papillary RCCs were misclassified and there was one pseudoenhancing cyst. With ΔHU ≥ 15 HU, no papillary RCCs were misclassified but 11.1% (3/27) of cysts showed pseudoenhancement. Only an iodine concentration of ≥ 2.0 mg/mL showed significantly lower accuracy than other measures (p = 0.031-0.045). CONCLUSION. DECT applied in the CM phase performed best using an iodine concentration of ≥ 1.2 mg/mL or a 70-keV ΔHU ≥ 15 HU; these parameters improved sensitivity for the detection of enhancement in renal masses without instances of cyst pseudoenhancement.

Evaluation of a free-breathing respiratory-triggered (Navigator) 3-D T1-weighted (T1W) gradient recalled echo sequence (LAVA) for detection of enhancement in cystic and solid renal masses

OBJECTIVES

To evaluate free-breathing Navigator-triggered 3-D T1-weighted MRI (NAV-LAVA) compared to breath-hold (BH)-LAVA among cystic and solid renal masses.

MATERIALS AND METHODS

With an IRB waiver, 44 patients with 105 renal masses (71 non-enhancing cysts and 14 cystic and 20 solid renal masses) underwent MRI between 2016 and 2017 where BH-LAVA and NAV-LAVA were performed. Subtraction images were generated for BH-LAVA and NAV-LAVA using pre- and 3-min post-gadolinium-enhanced images and were evaluated by two blinded radiologists for overall image quality, image sharpness, motion artifact, and quality of subtraction (using 5-point Likert scales) and presence/absence of enhancement. Percentage signal intensity change (Δ%SI) = ([SI.post-gadolinium-SI.pre-gadolinium]/SI.pre-gadolinium)*100, was measured on BH-LAVA and NAV-LAVA. Likert scores were compared using Wilcoxon's sign-rank test and accuracy for detection of enhancement compared using receiver operator characteristic (ROC) analysis.

RESULTS

Overall image quality (p = 0.002-0.141), image sharpness (p = 0.002-0.031), and motion artifact were better (p = 0.002) comparing BH-LAVA to NAV-LAVA for both radiologists; however, quality of image subtraction did not differ between groups (p = 0.09-0.14). Sensitivity/specificity/area under ROC curve for enhancement in cystic and solid renal masses using subtraction and %SIΔ were (1) BH-LAVA: 64.7%/98.6%/0.82 (radiologist 1), 61.8%/95.8%/0.79 (radiologist 2), and 70.6%/81.7%/0.76 (%SIΔ) versus 2) NAV-LAVA: 58.8%/95.8%/0.79 (radiologist 1, p = 0.16), 58.8%/88.7%/0.73 (radiologist 2, p = 0.37), and 73.5%/76.1%/0.75 (%SIΔ, p = 0.74).

CONCLUSIONS

NAV-LAVA showed similar quality of subtraction and ability to detect enhancement compared to BH-LAVA in renal masses albeit with lower image quality, image sharpness, and increased motion artifact. NAV-LAVA may be considered in renal MRI for patients where BH is suboptimal.

KEY POINTS

• Free-breathing Navigator (NAV) 3-D subtraction MRI is comparable to breath-hold (BH) images. • Accuracy for subjective and quantitative diagnosis of enhancement in renal masses on NAV 3-D T1W is comparable to BH MRI. • NAV 3-D T1W renal MRI is useful in patients who may not be able to adequately BH.

Trends in Renal-Cell Carcinoma Incidence and Mortality in the United States in the Last 2 Decades: A SEER-Based Study

BACKGROUND

Renal-cell carcinoma (RCC) is one of the common malignancies in the United States. RCC incidence and mortality have been changing for many reasons. We performed a thorough investigation of incidence and mortality trends of RCC in the United States using the cell Surveillance, Epidemiology, and End Results (SEER) database.

PATIENTS AND METHODS

The 13 SEER registries were accessed for RCC cases diagnosed between 1992 and 2015. Incidence and mortality were calculated by demographic and tumor characteristics. We calculated annual percentage changes of these rates. Rates were expressed as 100,000 person-years.

RESULTS

A total of 104,584 RCC cases were reviewed, with 47,561 deaths. The overall incidence was 11.281 per 100,000 person-years. Incidence increased by 2.421% per year (95% confidence interval, 2.096, 2.747; P < .001) but later became stable since 2008. However, the incidence of clear-cell subtype continued to increase (1.449%; 95% confidence interval, 0.216, 2.697; P = .024). RCC overall mortality rates have been declining since 2001. However, mortality associated with distant RCC only started to decrease in 2012, with an annual percentage change of 18.270% (95% confidence interval, -28.775, -6.215; P = .006).

CONCLUSION

Despite an overall increase in the incidence of RCC, there has been a recent plateau in RCC incidence rates with a significant decrease in mortality.

Contemporary update on imaging of cystic renal masses with histopathological correlation and emphasis on patient management

This article presents an updated review of cystic renal mass imaging. Most cystic renal masses encountered incidentally are benign and can be diagnosed confidently on imaging and require no follow-up. Hyperattenuating masses discovered at unenhanced or single-phase enhanced computed tomography (CT) measuring between 20-70 HU are indeterminate and can be further investigated first by using ultrasound and, then with multi-phase CT or magnetic resonance imaging (MRI); as the majority represent haemorrhagic/proteinaceous cysts (HPCs). Dual-energy CT may improve differentiation between HPCs and masses by suppressing unwanted pseudo-enhancement observed with conventional CT. HPCs can be diagnosed confidently when measuring >70 HU at unenhanced CT or showing markedly increased signal on T1-weighted imaging. Although the Bosniak criteria remains the reference standard for diagnosis and classification of cystic renal masses, histopathological classification and current management has evolved: multilocular cystic renal cell carcinoma (RCC) has been reclassified as a cystic renal neoplasm of low malignant potential, few Bosniak 2F cystic masses progress radiologically during follow-up; RCC with predominantly cystic components are less aggressive than solid RCC; and Bosniak III cystic masses behave non-aggressively. These advances have led to an increase in non-radical management or surveillance of cystic renal masses including Bosniak 3 lesions. Tubulocystic RCC is a newly described entity with distinct imaging characteristics, resembling a pancreatic serous microcystadenoma. Other benign cystic masses including: mixed epithelial stromal tumours (MEST) are now considered in the spectrum of cystic nephroma and angiomyolipoma (AML) with epithelial cysts (AMLEC) resemble a fat-poor AML with cystic components.